{
    "2018-05-08": [
        [
            {
                "time": "2018-04-01",
                "original_text": "Keytruda: Merck’s Immuno-Oncology Blockbuster Drug in 1Q18",
                "features": {
                    "keywords": [
                        "Keytruda",
                        "Merck",
                        "Immuno-Oncology",
                        "Blockbuster"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Celgene’s Otezla Witnessed Solid Growth in 1Q18",
                "features": {
                    "keywords": [
                        "Celgene",
                        "Otezla",
                        "Solid Growth"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Biogen’s Key Partnerships: Eisai, Pfizer, AbbVie, and Ionis",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Partnerships",
                        "Eisai",
                        "Pfizer",
                        "AbbVie",
                        "Ionis"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "Why Did Biogen and AbbVie Recall Zinbryta?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "AbbVie",
                        "Recall",
                        "Zinbryta"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "AbbVie to Present at the UBS Global Healthcare Conference",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "UBS",
                        "Global Healthcare Conference"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-01",
                "original_text": "How Analysts View Allergan after Its 1Q18 Earnings",
                "features": {
                    "keywords": [
                        "Allergan",
                        "Analysts",
                        "1Q18 Earnings"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}